Frontiers in Pharmacology (Sep 2022)

Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

  • Ningning Yan,
  • Siyuan Huang,
  • Linlin Li,
  • Qianqian Guo,
  • Di Geng,
  • Huixian Zhang,
  • Sanxing Guo,
  • Xingya Li

DOI
https://doi.org/10.3389/fphar.2022.898623
Journal volume & issue
Vol. 13

Abstract

Read online

Immune checkpoint inhibitors (ICIs) have greatly transformed the treatment and improved the prognosis for patients with non-small cell lung cancer (NSCLC) without driver gene alterations. However, the effects of ICI combination therapy in ROS1 fusion-positive NSCLC remains unclear. Herein, we present a case with ROS1 fusion-positive NSCLC treated with ICI plus chemotherapy. The patient achieved a continuous partial response (PR) to ICI plus chemotherapy and a more than 35 months progression free survival. This case demonstrates that ICI plus chemotherapy is a promising option for patients with ROS1 fusion-positive NSCLC.

Keywords